| Combining neratinib with CDK4/6, mTOR, and MEK inhibitors in models of HER2-positive cancer M Zhao, S Scott, KW Evans, E Yuca, T Saridogan, X Zheng, H Wang, ... Clinical Cancer Research 27 (6), 1681-1694, 2021 | 41 | 2021 |
| A classifier integrating plasma biomarkers and radiological characteristics for distinguishing malignant from benign pulmonary nodules Y Lin, Q Leng, Z Jiang, MA Guarnera, Y Zhou, X Chen, H Wang, W Zhou, ... International journal of cancer 141 (6), 1240-1248, 2017 | 41 | 2017 |
| Characteristics and outcomes of breast cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase I clinical trials F Lynce, MJ Blackburn, L Cai, H Wang, L Rubinstein, P Harris, C Isaacs, ... Breast cancer research and treatment 168, 35-41, 2018 | 8 | 2018 |
| Adaptive response to BET inhibition induces therapeutic vulnerability to MCL1 inhibitors in breast cancer G Yan, H Wang, A Luna, B Bozorgui, X Li, M Sanchez, Z Dereli, ... BioRxiv, 711895, 2019 | 6 | 2019 |
| Targeting adaptation to cancer treatment by drug combinations H Wang, A Luna, G Yan, X Li, O Babur, GB Mills, C Sander, A Korkut bioRxiv, 2021.04. 14.439861, 2021 | 3 | 2021 |
| BET inhibition induces vulnerability to MCL1 targeting through upregulation of fatty acid synthesis pathway in breast cancer G Yan, A Luna, H Wang, B Bozorgui, X Li, M Sanchez, Z Dereli, ... Cell reports 40 (11), 2022 | 2 | 2022 |
| Discovery of adaptive resistance pathways and anti-resistance combination therapies from phosphoproteomic data using graphical models A Luna, H Wang, O Babur, C Sander, A Korkut Cancer Research 79 (13_Supplement), 3820-3820, 2019 | | 2019 |
